Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00722306 · ClinicalTrials.gov registry record · Phase 1
A Study To Investigate The Absorption, Metabolism And Excretion Of [14C] PD 0200390 In Six Healthy Male Volunteers
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT00722306: Completed Phase 1 study, sponsored by Pfizer.
NCT00722306 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 6 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00722306, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
To determine the mass balance of PD 0200390
Interventions
- DRUG PD 0200390
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2008-05 |
| Est. Completion | 2008-05 |
| Phase | Phase 1 |
What the finished NCT00722306 record still lists
NCT00722306 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 1 intervention - of which PD 0200390 is the first listed.
NCT00722306 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00722306 about?
NCT00722306 is a clinical study titled "A Study To Investigate The Absorption, Metabolism And Excretion Of [14C] PD 0200390 In Six Healthy Male Volunteers". To determine the mass balance of PD 0200390
What is the current status of trial NCT00722306?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2008-05. Estimated completion is 2008-05.
What interventions are being tested in trial NCT00722306?
The interventions under investigation include: PD 0200390 (DRUG).
Who is sponsoring clinical trial NCT00722306?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00722306's enrollment target sits among peer trials
6 1974th of 2000 higher than 12 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia